143 related articles for article (PubMed ID: 12665686)
1. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors.
Fjällskog ML; Ludvigsen E; Stridsberg M; Oberg K; Eriksson B; Janson ET
Med Oncol; 2003; 20(1):59-67. PubMed ID: 12665686
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors.
Oda Y; Tanaka Y; Naruse T; Sasanabe R; Tsubamoto M; Funahashi H
Surg Today; 2002; 32(8):690-4. PubMed ID: 12181718
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility.
Nasir A; Stridsberg M; Strosberg J; Su PH; Livingston S; Malik HA; Kelley ST; Centeno BA; Coppola D; Malafa ME; Yeatman TJ; Kvols LK
Cancer Control; 2006 Jan; 13(1):52-60. PubMed ID: 16508627
[TBL] [Abstract][Full Text] [Related]
4. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Endocr Relat Cancer; 2003 Dec; 10(4):451-8. PubMed ID: 14713257
[TBL] [Abstract][Full Text] [Related]
6. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression.
Hansel DE; Rahman A; Hermans J; de Krijger RR; Ashfaq R; Yeo CJ; Cameron JL; Maitra A
Mod Pathol; 2003 Jul; 16(7):652-9. PubMed ID: 12861060
[TBL] [Abstract][Full Text] [Related]
7. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy.
Mundschenk J; Unger N; Schulz S; Höllt V; Schulz S; Steinke R; Lehnert H
J Clin Endocrinol Metab; 2003 Nov; 88(11):5150-7. PubMed ID: 14602742
[TBL] [Abstract][Full Text] [Related]
9. A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.
Körner M; Waser B; Christ E; Beck J; Reubi JC
Neuroendocrinology; 2018; 106(2):116-127. PubMed ID: 28384628
[TBL] [Abstract][Full Text] [Related]
10. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of somatostatin receptors in human ovarian tumors.
Schulz S; Schmitt J; Quednow C; Roessner A; Weise W
Gynecol Oncol; 2002 Feb; 84(2):235-40. PubMed ID: 11812080
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.
Papotti M; Kumar U; Volante M; Pecchioni C; Patel YC
Clin Endocrinol (Oxf); 2001 May; 54(5):641-9. PubMed ID: 11380495
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.
de Sá SV; Corrêa-Giannella ML; Machado MC; de Souza JJ; Pereira MA; Patzina RA; Siqueira SA; Machado MC; Giannella-Neto D
Endocr Relat Cancer; 2006 Mar; 13(1):69-78. PubMed ID: 16601280
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours.
Unger N; Serdiuk I; Sheu SY; Walz MK; Schulz S; Saeger W; Schmid KW; Mann K; Petersenn S
Clin Endocrinol (Oxf); 2008 Jun; 68(6):850-7. PubMed ID: 18031328
[TBL] [Abstract][Full Text] [Related]
17. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
[TBL] [Abstract][Full Text] [Related]
18. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats.
Ludvigsen E; Olsson R; Stridsberg M; Janson ET; Sandler S
J Histochem Cytochem; 2004 Mar; 52(3):391-400. PubMed ID: 14966206
[TBL] [Abstract][Full Text] [Related]
19. Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4.
Lupp A; Hunder A; Petrich A; Nagel F; Doll C; Schulz S
Neuroendocrinology; 2011; 94(3):255-64. PubMed ID: 21952553
[TBL] [Abstract][Full Text] [Related]
20. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
